The primary objectives of this study are to assess toxicity, determine maximum tolerated doses, and recommend phase II dosage for this combination. The objective response in those patients with measurable disease will also be assessed. The study is expected to enroll up to 48 patients.
“The favorable safety profile and clinical activity of satraplatin in several solid tumor types and the proven efficacy of Taxotere in various cancers make this a treatment regimen that has the potential to help many patients with cancer,” said Dr George Wilding, professor at the University of Wisconsin Comprehensive Cancer Center and joint investigative leader.
Satraplatin, an investigational drug, is a member of the platinum family of compounds. Over the past two decades, platinum-based drugs have become a critical part of modern chemotherapy treatments and are used to treat a wide variety of cancers. According to GPC Biotech, worldwide sales of these drugs exceeded $2.2 billion in 2004.
The drug is currently in a phase III trial investigating its potential as a second-line chemotherapy treatment for hormone-refractory prostate cancer. The FDA has granted fast track designation to satraplatin for this indication. However, the company is keen to investigate the drug’s efficacy in combination with a number of other compounds in cancers outside of Satraplatin’s initial indication.